BioCentury | Jan 23, 2019
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models A 3-D human tissue model that mimics beating adult myocardium could help assess the effects of heart disease therapies on myocardial contractility. Generation and use of the biomimetic model involves five steps:...
BioCentury | Jun 29, 2018
Tools & Techniques

QT replacement plan

FDA has completed validation of a preclinical assay system that could replace clinical QT testing, a move it hopes will lower development costs and reduce false alarms of arrhythmia risk. The question for drug developers...
BioCentury | Jun 6, 2016
Company News

Tetragenetics, Theranyx deal

The companies partnered to discover and develop therapeutic mAbs against Nav1.6 ( PN4 ; SCN8A ), potassium channel Kv10.1 (KCNH1) and other undisclosed ion channel targets. The partners said they will focus on pain and cancer...
BioCentury | Oct 1, 2015
Distillery Therapeutics

Therapeutics: Potassium channel Kv10.2 (KCNH5; EAG2)

...Cancer INDICATION: Brain cancer; cancer Mouse and patient sample studies suggest inhibiting KCNH5 could help treat...
...In a mouse xenograft model of medulloblastoma expressing high levels of KCNH5, shRNA knockdown of KCNH5...
...cancers. Mylan N.V. markets the generic antipsychotic thioridazine hydrochloride to treat schizophrenia. TARGET/MARKER/PATHWAY: Potassium channel Kv10.2 (KCNH5; EAG2...
BioCentury | Sep 21, 2015
Clinical News

Vanoxerine: Phase III started

Laguna began the double-blind, placebo-controlled, international Phase III RESTORE SR trial to evaluate a single dose of 400 mg oral vanoxerine in about 600 patients. Laguna Pharmaceuticals Inc. , La Jolla, Calif. Product: Vanoxerine ( GBR-12909 ) Business:...
BioCentury | May 7, 2015
Distillery Techniques

Techniques: Mutations in potassium channel Kv10.1 (KCNH1) and vacuolar H+ ATPase B2 (ATP6V1B2) as diagnostic markers of Zimmermann-Laband syndrome (ZLS)

Biomarkers KCNH1 ATP6V1B2 potassium channel Kv10.1 (KCNH1) University Medical Center Hamburg-Eppendorf BC Staff...
BioCentury | Feb 23, 2015

An acute arrhythmia alternative

Laguna Pharmaceuticals Inc. plans to use a $30 million series B round to conduct a confirmatory Phase III trial of vanoxerine for acute treatment of atrial fibrillation and atrial flutter. The company is initially targeting...
BioCentury | Feb 18, 2015
Financial News

Laguna raises $30M in B round

Laguna Pharmaceuticals Inc. (La Jolla, Calif.) raised $30 million in a series B round led by new investors Versant Ventures and Frazier Healthcare. New investor BioMed Ventures and existing investor Sante Ventures also participated. Formerly...
BioCentury | Feb 13, 2014
Tools & Techniques

Micromanaging the microenvironment

A Massachusetts team has designed an in vivo shRNA screen to discover immunosuppressive tumor targets that can be blocked to improve the efficacy of T cell immunotherapies. 1 The screening system shows that current checkpoint...
BioCentury | Dec 9, 2013
Clinical News

Vanoxerine: Phase IIb data

The double-blind, Israeli and Russian Phase IIb COR-ART trial in 104 patients with symptomatic AF or flutter of recent onset showed that single oral doses of GBR-12909 reduced time to conversion to normal sinus rhythm...
Items per page:
1 - 10 of 23